iRGD
iRGD tumor-penetrating peptide (CRGDKGPDC)
9 Amino Acids · MW: ≈1003 g/mol
Amino Acids
9
Molecular Weight
≈1003 g/mol
Half-life
minutes
Research Score
4.5
Studies
87
Storage
Store lyophilized at -20°C, reconstituted at 2-8°C
What is iRGD?
A cyclic tumor-penetrating peptide that first binds integrins and then activates an endocytic transport pathway through CendR-dependent uptake. It is frequently used to improve tumor penetration of co-administered drugs, nanoparticles, and peptide-drug conjugates.
Key Benefits & Mechanisms
tumor penetration
integrin targeting
payload deep-uptake
Research Summary
iRGD has repeatedly enhanced intratumoral accumulation of chemotherapeutics and biologics in preclinical cancer models, making it a leading tumor-penetrating motif for delivery research.
Related Peptides
GV1001
Human telomerase reverse transcriptase (hTERT) 611-626 peptide GV1001
A telomerase-derived 16-mer peptide developed as a cancer vaccine antigen. It is designed to trigger T-cell responses against hTERT-expressing tumors.
Cancer ResearchNelipepimut-S
HER2/neu-derived peptide vaccine Nelipepimut-S (E75; KIFGSLAFL)
A 9-mer HLA-A2/A3-restricted peptide from HER2/neu used as a vaccine antigen. It aims to expand cytotoxic T-cell responses against HER2-positive tumors.
Cancer ResearchWT1 peptide
Wilms tumor 1 (WT1) antigen-derived peptide RMFPNAPYL
A WT1-derived 9-mer peptide used in peptide-vaccine strategies for leukemias and solid tumors. It is intended to generate HLA-restricted cytotoxic T-cell responses against WT1-positive cancer cells.
Cancer ResearchSurvivin 2B peptide
Survivin 2B peptide (LMLGEFLKL)
A survivin-derived HLA-A24-restricted epitope investigated as a peptide vaccine antigen. It targets survivin, a frequently overexpressed inhibitor of apoptosis in tumors.
Cancer Research